FOLR1, folate receptor alpha, 2348

N. diseases: 174; N. variants: 8
Disease: Platinum-Resistant Ovarian Carcinoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4688007
Disease: Platinum-Resistant Ovarian Carcinoma
Platinum-Resistant Ovarian Carcinoma 		0.010 Biomarker disease BEFREE Reversible, low-grade ocular adverse events (AE) are associated with administration of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeted antibody-drug conjugate undergoing phase III clinical evaluation in platinum-resistant ovarian cancer. 30413525 2019